Rocuronium Bromide Injection, Solution
Product Images NDC 51662-1355
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Rocuronium Bromide (NDC 51662-1355). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
51662 1355 1 Vial Labeling Updated
This is a description of a medical product called "Vecuronium Bromide Injection" used as a muscle relaxant during anesthesia. It contains United States address and a warning message about possible allergic reactions. The rest of the text provides information about the product's identification code and its manufacturing details.*
C1 (Clinical Pharm 1)
C2 (Clinical Pharm 2)
This appears to be a table showing the dose, time to a certain level of muscle block, time to maximum block, and clinical duration of the muscle relaxant drug Rocuronium Bromide, administered intravenously in different doses for adults, geriatric patients, infants, and pediatric patients. However, without further context or explanation of the units used, it is difficult to provide a more detailed description.*
C10 (Clinical Pharma 10)
This appears to be a table showing pharmacokinetic (PK) parameters for patients in different age ranges, listed in days, months, and years. The table includes information on clearance (CL), volume of distribution (O), and half-life (1/2 B) for patients between 28 days old and 17 years old. The numbers in parentheses likely represent a range or variability in the values.*
C3 (Clinical Pharma 3)
This appears to be a chart showing the recommended dosage of rocuronium bromide for different age groups, from neonates to adolescents. It also shows the time it takes for maximum block and reappearance of T3 after administration over a period of time. However, some of the text is cut off, making it difficult to interpret some of the values.*
C4 (Clinical Pharma 4)
C5 (Clinical Pharma 5)
This is a figure showing the duration of clinical effect versus the initial dose of Rocuronium Bromide by age group. Median, 25th, and 75th percentiles, as well as individual values, are displayed. The age groups are categorized as 18-64 years, greater than or equal to 65 years, 3 months to 1 year, and 1-12 years, along with the dosages in milligrams per kilogram.*
C6 (Clinical Pharma 6)
C7 (Clinical Pharma 7)
This is a table that shows PK (pharmacokinetic) parameters for a certain drug in two groups of people: adults (aged 27-58 years) and geriatrics (aged 65 years and above). The table displays the clearance (L/kg/hr), volume of distribution at steady-state (L/kg), and half-life of elimination (hr) of the drug in each group.*
C8 (Clinical Pharma 8)
C9 (Clinical Pharma 9)
Dosage 1 (Dosage And Administration 1)
This appears to be a table indicating the infusion delivery rate (mL/hr) for drug dosages based on the patient's weight (in pounds) and drug delivery rate (mcg/kg/min). The first row lists patient weights from 45 to 160 pounds in increments of 10, while the first column lists drug delivery rates from 4 to 100 mcg/kg/min in increments of 5. However, the table is not complete, as some values are missing.*
Dosage 2 (Dosage And Administration 2)
Dosage 3 (Dosage And Administration 3)
Highlights (Highlights)
Logo (Logo)
Serialized Label (Serialized 10 mL Vial Label)
Serialized Vial Labeling 51662 1355 1 Update
Structure (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.